^
    13d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    17d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    18d
    DFCI 21-757: Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov)
    P1, N=30, Recruiting, Andrew E. Place, MD | Active, not recruiting --> Recruiting | N=13 --> 30 | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Pan tumor
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    KMT2A rearrangement • ABL1 fusion
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
    24d
    CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=7, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Oct 2026
    Enrollment open • Trial primary completion date
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Asparlas (calaspargase pegol-mknl)
    27d
    B2019-148: Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2027
    Enrollment closed • Trial completion date
    |
    gemcitabine • Tyvyt (sintilimab) • oxaliplatin • Oncaspar liquid (pegaspargase)
    1m
    SPARK-ALL: Calaspargase Pegol in Adults With ALL (clinicaltrials.gov)
    P2/3, N=42, Terminated, Institut de Recherches Internationales Servier | N=122 --> 42 | Trial completion date: Feb 2026 --> Mar 2025 | Active, not recruiting --> Terminated; Sponsor decision
    Enrollment change • Trial completion date • Trial termination
    |
    Asparlas (calaspargase pegol-mknl)
    2ms
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    4ms
    CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Asparlas (calaspargase pegol-mknl)
    4ms
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    Asparlas (calaspargase pegol-mknl)
    5ms
    Efficacy and safety of DAPT regimen (dexamethasone, azacitidine, pegaspargase, tislelizumab) for NK/T cell lymphoma (ChiCTR2500109853)
    P2, N=50, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • azacitidine • Oncaspar liquid (pegaspargase)
    5ms
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic
    New trial
    |
    Asparlas (calaspargase pegol-mknl)
    5ms
    CASPER: Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Cotellic (cobimetinib) • Asparlas (calaspargase pegol-mknl)